COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

MRNA-1273.213 is under clinical development by Moderna and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Five years after the virus that causes COVID emerged in China it still holds some mysteries. The disease has killed an ...

Biontech SE agreed to pay up to nearly $1.26 billion in two separate settlements to resolve royalty disputes with the U.S. NIH and the University of Pennsylvania related to the COVID-19 vaccine the ...

SK Bioscience Co. Ltd. won €50 million (₩75.5 billion, US$52.03 million) up front from Sanofi SA to expand an earlier ...

Middlemen get a bad rap for adding cost and complications to an operation. So, eliminating the go-betweens can reduce expense and simplify a process, increasing efficiency and consumer happiness.

a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and ...

Russia announces the development of an mRNA cancer vaccine, slated for a 2025 launch. Pre-clinical trials demonstrate tumor suppression and metastasis reduction. AI integration promises to ...

The vaccine will reportedly be used to treat cancer patients rather than given to the public to prevent cancer. Andrey Kaprin, the General Director of the Radiology Medical Research Centre of the ...

Russia announced that it is planning to complete the development of an mRNA cancer vaccine and launch it in 2025. "Russia has developed its own mRNA vaccine against cancer, it will be distributed to ...